Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Obesity (Silver Spring). 2020 Jul;28(7):1254–1262. doi: 10.1002/oby.22854

Figure 1. CONSORT Study selection diagram.

Figure 1.

Healthy obese adults without type 2 diabetes were screened for eligibility in the trial and 40 were randomized to empagliflozin/matching placebo. Four participants did not return for follow-up procedures and 1 participant was excluded immediately after randomization due to diagnosis of type 2 diabetes. 35 participants (18 empagliflozin/17 matching placebo) had full data available for the modified intention-to-treat analysis.